GKOS

Glaukos Corporation

HALAL

Score: 82/100

stock

Is GKOS Halal?

Developer of micro-invasive ophthalmic medical devices and pharmaceutical therapies for glaucoma and corneal disease — a permissible medical-technology business, with the financial screen as the primary consideration.

What You Should Know

Glaukos Corporation is a publicly-traded ophthalmic medical-technology and pharmaceutical company focused on novel therapies for glaucoma, corneal disorders, and retinal disease, including its micro-invasive glaucoma-surgery (MIGS) implant devices, corneal-health products (such as its cross-linking therapy for keratoconus), and a pipeline of drug-delivery and pharmaceutical candidates. Medical-device manufacturing, ophthalmic-implant development, and pharmaceutical-therapy development are general-purpose healthcare and medical-technology activities that are unambiguously permissible — and indeed beneficial — at the activity level under standard Sharia methodology. The financial screen is the principal consideration: Glaukos is an emerging-growth company that has issued convertible debt to fund its pipeline and is not yet consistently profitable, so the debt-to-market-cap ratio and the interest-income and liquidity ratios should be verified against the Sharia thresholds at the time of investment. Subject to that verification, most major Sharia advisory boards classify Glaukos as permissible with purification of small interest-income components.

⚠️ Concerns

•Debt-to-market-cap ratio should be verified against the 33% Sharia threshold at the time of investment — Glaukos has issued convertible debt to fund its R&D pipeline; this is a primary Sharia-screening consideration, and convertible instruments warrant particular attention
•Interest-income-to-revenue and liquidity ratios should be checked against the relevant thresholds and the investment portfolio confirmed to be in Sharia-acceptable instruments — Glaukos maintains a sizable cash-and-investments position relative to its still-growing revenue base
•Glaukos is an emerging-growth medical-technology company that is not yet consistently profitable and reinvests heavily in R&D — this is a business and valuation consideration rather than a Sharia screen concern
•The business depends on reimbursement, regulatory approvals, clinical-trial outcomes, and physician-adoption — these are business and regulatory considerations rather than Sharia screen concerns
•The stock frequently trades at a premium growth valuation and can be highly volatile — this is a valuation consideration rather than a Sharia screen concern
•Receivables-to-assets ratio should be checked against the preferred board's threshold at the time of investment